S3 E5: Lou Garrison and the Possibility of a U.S. Health Technology Assessment
Calls for more involvement from the United States government in how medicines are priced have inevitably given rise to questions about the infrastruct...
Redeeming Value
Share:
Listens: 3
About
W2O Group's regular look at the value and access conversation in health care, with Brian Reid and Rita Glaze, the leaders of the W2O Value+Access Practice.
S3 E4: Discern's Christine Juday on Value-Based Insurance Design
Value-based insurance design (VBID) uses incentives to increase health care quality and to promote cost efficient health care services and consumer ch...
S3 E3: Brad Loncar on Whether Pricing Pressure is Coming in Oncology
Launch prices in oncology have been rising -- a reflection, in part, of the growing clinical power of the medicines -- raising the question whether do...
S3 E2 Peter Pitts on His New Book, "The Value Equation"
The COVID-19 pandemic has served as a wake-up call for the healthcare ecosystem to recognize the urgencies of working together to achieve life-changin...
S3 E1: West Health's Sean Dickson Discusses Medicaid Rebate Caps
Early legislative language from the House of Representatives on the newest COVID-19 stimulus bill includes a provision to remove the "rebate cap" in M...
S2 E6 W2O's Courtney Tyne with Instant Analysis on the Election Results (So Far)
Well, it's 2020, so it shouldn't be surprising that the United States awoke the morning after Election Day to uncounted ballots and unanswered questio...
S2 E5: AAM's Dan Leonard on What's Next for Generic Drugs and Biosimilars
The Association for Accessible Medicines' new president and CEO, Dan Leonard, goes behind the mic to talk about the pathway to his new gig, the promis...
S2 E4: Ted Slafsky on 340B, How We Got Here, and Where We're Going
Brian talks to Ted Slafsky, the founder and principal of Wexford Solutions and publisher and CEO of 340B Report. 340B -- the program under which certa...
S2 E3: Peter Kolchinsky on Where Drug-Pricing Policy Solutions Go Wrong
Peter Kolchinsky, RA Capital's founder and managing partner, joins to talk about why so many of the policy ideas floated around drug-pricing are wrong...
S2 E2: Jason Shafrin on Where -- and Why -- ICER Really Matters
precisionHEOR Vice President Jason Shafrin pops in to talk about the Institute of Clinical and Economic Review and the broader question of where the g...